Kos Pharmaceuticals
CompanyUnited States
Kos Pharmaceuticals develops one asset, approved (simvastatin in cerebrovascular disease). Mostly small molecule acting on lipid and ceramide metabolism, PPARA and AGTR1; based in the United States.
- 1
- Asset
- Furthest
- Approved
- 2
- Trials
- 0
- Signals
Pipeline
1HMG-CoA reductase inhibitor and PPAR-alpha agonist combination regulating lipid metabolism.
Approved, Small molecule, Lipid and ceramide metabolism, PPARA, cerebrovascular disease, coronary heart disease
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms4
- Trials4
- Similar companies6
Updated 8 Oct 2026 · 45 sources